PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
News|Articles|June 8, 2020
Novavax Secures $60 Million in Government Funds
Author(s)Pharmaceutical Technology Editors
Novavax announces DoD contract to produce 10 million doses of COVID-19 vaccine candidate.
Advertisement
Novavax announced a $60 million contract with the US Department of Defense to support the production of several components of NVXâCoV2373, its COVID-19 vaccine candidate. The agreement includes delivery in 2020 of 10 million doses of NVXâCoV2373 that can be used in Phase 2/3 clinical trials or under an Emergency Use Authorization if approved by FDA.
In a June 4, 2020 press statement, Novavax reported that the company will work with US-based contract development manufacturing organizations (CDMOs) to manufacture the antigen component of NVX-CoV2373 for at least 10 million doses of vaccine and will collaborate with US-based CDMOs to scale up production and manufacture of the Matrix-M adjuvant component of the vaccine.
Previously,
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Advertisement
Advertisement